Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Transcription Factor RUNX1 Regulates Coagulation Factor XIII-A ( F13A1 ): Decreased Platelet-Megakaryocyte F13A1 Expression and Clot Contraction in RUNX1

View through CrossRef
Abstract Background Germline RUNX1 haplodeficiency (RHD) is associated with thrombocytopenia, platelet dysfunction and predisposition to myeloid malignancies. Platelet expression profiling of a RHD patient showed decreased F13A1, encoding for the A subunit of factor XIII, a transglutaminase that cross-links fibrin and induces clot stabilization. FXIII-A is synthesized by hematopoietic cells, megakaryocytes and monocytes. Aims To understand RUNX1 regulation of F13A1 expression in platelet/megakaryocyte and the mechanisms and consequences of decreased F13A1 in RHD. Methods We performed studies in platelets, HEL cells and human CD34+ cell-derived megakaryocytes including on clot contraction in cells following small inhibitor (si)RNA knockdown (KD) of RUNX1 or F13A1 . Results Platelet F13A1 mRNA and protein were decreased in our index patient and in two siblings from an unrelated family with RHD. Platelet-driven clot contraction was decreased in the patient and affected daughter. Promoter studies in HEL cells showed that RUNX1 regulates F13A1 transcription; RUNX1 overexpression increased and (si)RNA RUNX1 KD reduced F13A1 promoter activity and protein. Following RUNX1 or F13A1 KD clot contraction by HEL cells was decreased as were FXIII-A surface expression, myosin light chain phosphorylation and PAC1 binding upon activation. F13A1 expression and clot contraction were impaired on RUNX1 downregulation in human megakaryocytes. Conclusions RUNX1 regulates platelet-megakaryocyte F13A1 expression, which is decreased in RHD, reflecting regulation of a coagulation protein by a hematopoietic transcription factor. Platelet and megakaryocyte clot contraction is decreased in RHD, related to multiple impaired mechanisms including F13A1 expression, myosin phosphorylation and αII b β 3 activation. Scientific category – Platelets and thrombopoiesis Essentials RUNX1 regulates expression of FXIII-A chain ( F13A1) in megakaryocytes (MK) and platelets. Platelet and MK F13A1 expression and clot contraction are decreased in RUNX1 deficiency. MK clot contraction, myosin phosphorylation and PAC1-binding are impaired in F13A1 deficiency. Defective clot contraction in RHD arises from defects in multiple platelet-MK mechanisms.
Title: Transcription Factor RUNX1 Regulates Coagulation Factor XIII-A ( F13A1 ): Decreased Platelet-Megakaryocyte F13A1 Expression and Clot Contraction in RUNX1
Description:
Abstract Background Germline RUNX1 haplodeficiency (RHD) is associated with thrombocytopenia, platelet dysfunction and predisposition to myeloid malignancies.
Platelet expression profiling of a RHD patient showed decreased F13A1, encoding for the A subunit of factor XIII, a transglutaminase that cross-links fibrin and induces clot stabilization.
FXIII-A is synthesized by hematopoietic cells, megakaryocytes and monocytes.
Aims To understand RUNX1 regulation of F13A1 expression in platelet/megakaryocyte and the mechanisms and consequences of decreased F13A1 in RHD.
Methods We performed studies in platelets, HEL cells and human CD34+ cell-derived megakaryocytes including on clot contraction in cells following small inhibitor (si)RNA knockdown (KD) of RUNX1 or F13A1 .
Results Platelet F13A1 mRNA and protein were decreased in our index patient and in two siblings from an unrelated family with RHD.
Platelet-driven clot contraction was decreased in the patient and affected daughter.
Promoter studies in HEL cells showed that RUNX1 regulates F13A1 transcription; RUNX1 overexpression increased and (si)RNA RUNX1 KD reduced F13A1 promoter activity and protein.
Following RUNX1 or F13A1 KD clot contraction by HEL cells was decreased as were FXIII-A surface expression, myosin light chain phosphorylation and PAC1 binding upon activation.
F13A1 expression and clot contraction were impaired on RUNX1 downregulation in human megakaryocytes.
Conclusions RUNX1 regulates platelet-megakaryocyte F13A1 expression, which is decreased in RHD, reflecting regulation of a coagulation protein by a hematopoietic transcription factor.
Platelet and megakaryocyte clot contraction is decreased in RHD, related to multiple impaired mechanisms including F13A1 expression, myosin phosphorylation and αII b β 3 activation.
Scientific category – Platelets and thrombopoiesis Essentials RUNX1 regulates expression of FXIII-A chain ( F13A1) in megakaryocytes (MK) and platelets.
Platelet and MK F13A1 expression and clot contraction are decreased in RUNX1 deficiency.
MK clot contraction, myosin phosphorylation and PAC1-binding are impaired in F13A1 deficiency.
Defective clot contraction in RHD arises from defects in multiple platelet-MK mechanisms.

Related Results

PATHOPHYSIOLOGY OF THROMBOCYTOPENIA AND RESULTANT CLINICAL INDICATIONS FOR PLATELET TRANSFUSION
PATHOPHYSIOLOGY OF THROMBOCYTOPENIA AND RESULTANT CLINICAL INDICATIONS FOR PLATELET TRANSFUSION
Careful evaluation of platelet survival data in normal individuals and patients with thrombocytopeniasecondary to marrow aplasia has demonstrated that platelets are lost from circu...
Expression of RUNX1-RUNX1T1 Alone Has No Effect on the Intrinsic Susceptibility to Cytotoxic Chemicals.
Expression of RUNX1-RUNX1T1 Alone Has No Effect on the Intrinsic Susceptibility to Cytotoxic Chemicals.
Abstract The RUNX1 gene (aka AML1 on chromosome 21) encodes the alpha component of the Core Binding Factor (CBF) complex. This heterodimeric transcription factor is ...
Therapeutic Targeting of RUNX-NFATC2 Axis for Acute Promyelocytic Leukemia and T Cell Immunity
Therapeutic Targeting of RUNX-NFATC2 Axis for Acute Promyelocytic Leukemia and T Cell Immunity
Runt-related transcription factor (RUNX) play pivotal roles in leukemogenesis and inhibition of RUNX has now been widely recognized as a novel strategy in anti-leukemic therapies. ...
Clot retraction facilitates clot lysis
Clot retraction facilitates clot lysis
Platelet facilitation of clot lysis was studied using the dilute clot lysis assay, a standardized assay for fibrinolysis shown to correlate with the development of postoperative de...
Clot retraction facilitates clot lysis
Clot retraction facilitates clot lysis
Abstract Platelet facilitation of clot lysis was studied using the dilute clot lysis assay, a standardized assay for fibrinolysis shown to correlate with the develop...
Abstract WP302: Different Clot Characteristics According to the Clot Volume: A Microscopic Analysis of Clot Composition
Abstract WP302: Different Clot Characteristics According to the Clot Volume: A Microscopic Analysis of Clot Composition
Background and Objectives: Understanding the mechanisms of thrombosis is crucial for the future advancement in treating ischemic stroke. While many researches on thromb...
Tranexamic Acid Increases Clot Stability in Patients with Severe Hemophilia A.
Tranexamic Acid Increases Clot Stability in Patients with Severe Hemophilia A.
Abstract Patients with severe Hemophilia A have a compromised clot formation. In addition, it is suggested that severe Hemophilia A is associated with reduced clot s...

Back to Top